Table 1.
Sperm parameters and prevalence of HPV DNA in the semen fluid of patients before and after 3 months of either treatment with ellagic acid (100 mg) and Annona muricata (100 mg) (Group A), or observation only (Group B).
| Parameters | Group A | Group B | Reference Values | ||
|---|---|---|---|---|---|
| Before Treatment | After Treatment | Before Treatment | After Treatment | ||
| Presence of HPV DNA | 25/25 (100%) | 12/25 (48%) * | 25/25 (100%) | 22/25 (88%) | / |
| Sperm concentration (mil/mL) | 30.8 ± 13.0 | 48.2 ± 13.0 * | 27.8 ± 6.0 | 23.2 ± 8.0 | >15 |
| Sperm progressive motility (%) | 15.2 ± 8.0 | 32.0 ± 8.0 * | 16.4 ± 11.0 | 14.5 ± 7.0 | >32 |
| Sperm normal morphology (%) | 11.6 ± 9.0 | 18.2 ± 10.0 * | 12.8 ± 8.0 | 13.2 ± 6.0 | >40 |
| Mixed antiglobulin reaction test (number of positive) | 7/25 (28%) | 1/25 (4%) * | 5/25 (20%) | 5/25 (20%) | / |
| Sperm DNA fragmentation (%) | 4.3 ± 0.4 | 1.6 ± 0.8 * | 4.1 ± 1.6 | 4.4 ± 1.2 | <4.6 |
* p < 0.05 vs. Group B after treatment.